Science Explorer Back to mapMap
Discussion
Institution · Ipsen (France)

Most cited papers from Ipsen (France)

Ipsen (France)

What are the most cited papers from Ipsen (France)?

The most cited paper from Ipsen (France) is "Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors" (Martyn Evan Caplin, Marianne Ellen Pavel, Jarosław Bogdan Ćwikła et al., 2014), with 1,954 citations. Next come "Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial" (1,375) and "Oxidative stress and Alzheimer disease" (1,169).

Showing 50 of 60 papers. Every paper with more than 135 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors Martyn Evan Caplin, Marianne Ellen Pavel, Jarosław Bogdan Ćwikła et al. · New England Journal of Medicine Open access 11 Jul 2014 1,954
2 Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial Piet Ost, Dries Reynders, Karel Decaestecker et al. · Journal of Clinical Oncology 14 Dec 2017 1,375
3 Oxidative stress and Alzheimer disease Yves Christen · American Journal of Clinical Nutrition Open access Feb 2000 1,169
4 The Nitric Oxide-Scavenging Properties of Ginkgo Biloba Extract EGb 761 Lucia Marcocci, John J. Maguire, Marie Therese Droy-Lefaix et al. · Biochemical and Biophysical Research Communications Jun 1994 1,049
5 Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes M. Sasso, Michel Beaugrand, Victor de Lédinghen et al. · Ultrasound in Medicine & Biology 28 Sep 2010 871
6 Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis Ferenc Emil Mózes et al. · Gut ReviewOpen access 17 May 2021 520
7 Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005 Lieven Annemans, Erik Spaepen, M. Gaskin et al. · Annals of the Rheumatic Diseases Open access 3 Nov 2007 500
8 Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber et al. · Journal of Clinical Oncology Open access 6 Apr 2017 475
9 Amyloid-β-Induced Pathological Behaviors Are Suppressed byGinkgo bilobaExtract EGb 761 and Ginkgolides in TransgenicCaenorhabditis elegans Yanjue Wu, Zhixin Wu, Peter Butko et al. · Journal of Neuroscience Open access 13 Dec 2006 415
10 Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial Bruno J. Vellas, Nicola Coley, Pierre‐Jean Ousset et al. · The Lancet Neurology Open access 6 Sep 2012 399
11 Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis Vassilios D. Papadopoulos, Hakima Amri, N. Boujrad et al. · Steroids Open access 1997 386
12 The ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β‐amyloid Stéphane Bastianetto, Charles Ramassamy, Sylvain Doré et al. · European Journal of Neuroscience Jun 2000 378
13 Peptide therapeutics: Targeting the undruggable space Natia Tsomaia · European Journal of Medicinal Chemistry 9 Jan 2015 356
14 SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer Guy A. Van Hazel et al. · Journal of Clinical Oncology 22 Feb 2016 352
15 Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial Kōichi Goto et al. · Journal of Clinical Oncology Open access 11 Sep 2023 323
16 Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers Michèle Sabbah, Shahin Emami, Gérard Redeuilh et al. · Drug Resistance Updates Aug 2008 320
17 Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. Serge Adnot, Bernadette Raffestin, Saadia Eddahibi et al. · Journal of Clinical Investigation Open access 1991 315
18 Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis Kris V. Kowdley et al. · New England Journal of Medicine 13 Nov 2023 299
19 Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano et al. · Journal of Clinical Oncology Open access 17 Jun 2020 299
20 Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort Stephen A. Harrison, Samer Gawrieh, Katharine K Roberts et al. · Journal of Hepatology 19 Mar 2021 293
21 The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan® M. Sasso, Véronique Miette, Laurent Sandrin et al. · Clinics and Research in Hepatology and Gastroenterology 16 Sep 2011 285
22 Treatment of carcinoid syndrome Dermot O’Toole, Michel Pierre Ducreux, Gilles Bommelaer et al. · Cancer 15 Feb 2000 275
23 Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis David Petroff et al. · ˜The œLancet. Gastroenterology & hepatology ReviewOpen access 18 Jan 2021 267
24 Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer’s disease is related to the apolipoprotein E genotype Charles Ramassamy, Diana A. Averill‐Bates, Uwe Beffert et al. · Free Radical Biology and Medicine Sep 1999 242
25 Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1 Alex Sparreboom · Clinical Pharmacology & Therapeutics Jul 2004 240
26 Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761 Indrani Maitra, Lucia Marcocci, Marie Therese Droy-Lefaix et al. · Biochemical Pharmacology May 1995 239
27 Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study Martyn Evan Caplin, Marianne Ellen Pavel, Jarosław Bogdan Ćwikła et al. · Endocrine Related Cancer Open access 7 Jan 2016 237
28 Cardioprotective and Anti-oxidant Effects of the Terpenoid Constituents ofGinkgo bilobaExtract (EGb 761) Sylvia Pietri, Eziana Maurelli, Katy Drieu et al. · Journal of Molecular and Cellular Cardiology Feb 1997 235
29 Ginkgo biloba extracts and cancer: a research area in its infancy Francis Vincent DeFeudis, Vassilios D. Papadopoulos, Katy Drieu · Fundamental and Clinical Pharmacology 7 Jul 2003 234
30 Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma Vasiliki Panou et al. · Journal of Clinical Oncology Open access 16 Aug 2018 232
31 Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial Jean‐Michel Graciès, Allison Brashear, Robert Jech et al. · The Lancet Neurology Open access 26 Aug 2015 226
32 Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C M. Sasso, Iulia Tengher-Barna, Marianne Ziol et al. · Journal of Viral Hepatitis 13 Oct 2011 216
33 Nitric oxide synthases: targets for therapeutic strategies in neurological diseases Pierre Etienne Chabrier, Caroline Demerlé-Pallardy, Teresa Auguet · Cellular and Molecular Life Sciences Open access 1999 215
34 A Ginkgo Biloba Extract (EGb 761) Prevents Mitochondrial Aging by Protecting Against Oxidative Stress Juan Sastre, Arantxa Millan, José García de la Asunción et al. · Free Radical Biology and Medicine 1998 209
35 Searching for star-planet interactions within the magnetosphere of HD 189733 R. Farès, J.‐F. Donati, C. Moutou et al. · Monthly Notices of the Royal Astronomical Society Open access 12 May 2010 208
36 EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease Flaubert Tchantchou, Yanan Xu, Yanjue Wu et al. · The FASEB Journal 13 Mar 2007 205
37 Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer Kyle Clifford Cuneo, Meredith Ann Morgan, Vaibhav Sahai et al. · Journal of Clinical Oncology Open access 9 Aug 2019 203
38 Oxidative Insults Are Associated with Apolipoprotein E Genotype in Alzheimer's Disease Brain Charles Ramassamy, Diana A. Averill‐Bates, Uwe Beffert et al. · Neurobiology of Disease Open access Feb 2000 196
39 Magnetic cycles of the planet-hosting star τ Bootis J.‐F. Donati, C. Moutou, R. Farès et al. · Monthly Notices of the Royal Astronomical Society Open access 25 Feb 2008 195
40 The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors Michel Pierre Ducreux, Philippe B Ruszniewski, Jean-Alain Chayvialle et al. · The American Journal of Gastroenterology Nov 2000 192
41 High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects Barbro K. Eriksson, J. Renstrup, Hasan Imam et al. · Annals of Oncology Open access Oct 1997 190
42 Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial Philippe Jean Caron, John Stuart Bevan, Stephan Petersenn et al. · The Journal of Clinical Endocrinology & Metabolism Open access 19 Dec 2013 188
43 A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines Benjamin Ascher, Benjamin Zakine, Philippe Kestemont et al. · Journal of the American Academy of Dermatology 27 Jul 2004 184
44 The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from β-amyloid-induced cell death by inhibiting the formation of β-amyloid-derived diffusible neurotoxic ligands Zhixing Yao, Katy Drieu, Vassilios D. Papadopoulos · Brain Research 2001 180
45 Final Height after Long-Term Treatment with Triptorelin Slow Release for Central Precocious Puberty: Importance of Statural Growth after Interruption of Treatment Jean‐Claude Carel, Marc Roger, S. Ispas et al. · The Journal of Clinical Endocrinology & Metabolism Jun 1999 174
46 LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson’s disease Fiona Bonello, Sidi-Mohamed Hassoun, François Mouton‐Liger et al. · Human Molecular Genetics 8 Jan 2019 166
47 Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518 James C. Yao, Katherine Adams Guthrie, César A. Moran et al. · Journal of Clinical Oncology Open access 6 Apr 2017 166
48 Oral passive IgY-based immunotherapeutics Shofiqur Rahman, Sa V. Nguyen, Faustino C. Icatlo et al. · Human Vaccines & Immunotherapeutics Open access 30 Jan 2013 165
49 Botulinum toxin A for treatment of upper limb spasticity following stroke: A multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes Paul Robert McCrory, Lynne Turner‐Stokes, Ian James Baguley et al. · Journal of Rehabilitation Medicine Open access 2009 165
50 Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy Meritxell Bellet, Kathryn P. Gray, Prudence A. Francis et al. · Journal of Clinical Oncology Open access 5 Jan 2016 163

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.